Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Corbus Pharmaceuticals Hldgs Inc (CRBP)

Corbus Pharmaceuticals Hldgs Inc (CRBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference

CRBP : 16.99 (+5.66%)
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

CRBP : 16.99 (+5.66%)
Corbus Pharmaceuticals: Q3 Earnings Snapshot

Corbus Pharmaceuticals: Q3 Earnings Snapshot

CRBP : 16.99 (+5.66%)
Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update

CRBP : 16.99 (+5.66%)
Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

CRBP : 16.99 (+5.66%)
Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

CRBP : 16.99 (+5.66%)
Up 174% in 2024, Is It Too Late to Buy This Breakout Biotech Stock?

After more than doubling in the past year, is this clinical-stage biotech stock still a buy?

CRBP : 16.99 (+5.66%)
$SPX : 5,953.73 (+0.62%)
NVO : 103.15 (-2.01%)
MRK : 99.11 (+1.71%)
LLY : 749.99 (-0.45%)
ABBV : 171.98 (+2.52%)
PFE : 25.03 (+0.36%)
XBI : 94.67 (+0.70%)
BMY : 58.29 (+0.71%)
Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

CRBP : 16.99 (+5.66%)
Corbus Pharmaceuticals: Q2 Earnings Snapshot

Corbus Pharmaceuticals: Q2 Earnings Snapshot

CRBP : 16.99 (+5.66%)
Up Over 700% YTD, Here's How Much Higher Analysts Think This Biotech Stock Can Rise

As the biotech industry rebounds from recent challenges, a favorable regulatory environment and groundbreaking scientific advancements are creating investment opportunities, particularly in companies with...

CRBP : 16.99 (+5.66%)

Barchart Exclusives

ELF’s Unusual Options Activity Is a Thing of Questionable Beauty
E.L.F. Beauty’s options volume on Wednesday was 7x the 30-day average. The affordable makeup and skincare company’s unusual options activity stood out as one investor questioned its revenues. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar